Candriam SCA’s ImmunityBio IBRX Stock Holding History

Candriam SCA’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-232,400	Closed	-$270K	–	811
2018 Q4	$270K	Buy	+232,400	New	+$532K	﹤0.01%	755

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Candriam SCA's IBRX Position: Q1 2019 in Review

Candriam SCA sold out of ImmunityBio (IBRX) in Q1 2019, closing a stake of 232,400 shares — an estimated $270K sold.

Candriam SCA first reported a position in IBRX in Q4 2018 and held it in 1 quarter. The position peaked at $270K in Q4 2018. 58 funds tracked by Wall St. Rank hold IBRX as of Q1 2019.

Candriam SCA reported no remaining ImmunityBio position as of Q1 2019 after selling out during the quarter.
Candriam SCA sold 232,400 ImmunityBio shares in Q1 2019, an estimated $270K.
Candriam SCA first reported a position in ImmunityBio in Q4 2018 and held it in 1 quarter.
Candriam SCA's ImmunityBio position peaked at $270K in Q4 2018.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2019.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.